Effect of cimetidine on pharmacokinetics of orally administered cyclosporine in healthy dogs

American Journal of Veterinary Research

Volumn 62, Issue 7, 2001, Pages 1046-1050

  Daigle, Jenise Coyne ^a   Hosgood, Giselle ^a   Foil, Carol S ^a   Hunter, Robert P ^b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYCLOSPORIN A;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG MONITORING; FEMALE; MALE; NONHUMAN;

EID: 0034961330     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2001.62.1046     Document Type: Article

References (33)

1. Bar-meir S, Bardan E, et al. Cimetidine and omeprazole do not effect CyA disposition by the rat liver. Eur J Drug Metab Pharmacokinet 1993;18:335-358.
2. Dahlinger J, Gregory C, Bea J. Effect of ketoconazole on CyA dose in healthy dogs. Vet Surg 1998;27:64-68.
3. Van Joost T, Kozel MA, Tamk B, et al. CyA in atopic dermatitis. J Am Acad Dermatol 1992;27:922-928.
4. McAnulty JF, Lensmeyer GL. The effects of ketoconazole on the pharmacokinetics of cyclosporine A in Cats. Vet Surg 1999; 28:448-455.
5. Kay AB. Immunosuppressive agents in chronic severe asthma. Allergy Proc 1994;15:147-150.
6. Mathews KA, Sukhiani HR. Randomized controlled trial of CyA for treatment of perianal fistulas in dogs. J Am Vet Med Assoc 1997;10:1249-154.
7. Gregory CR, Gourley IM. Renal transplantation in clinical veterinary medicine. In: Kirk RW, Bonagura JD, eds. Current veterinary therapy XI. Small animal practice. Philadelphia: WB Saunders Co, 1992;870-875.
8. Somogyi A, Gugler R. Drag interactions with cimetidine. Clin Pharmacol Ther 1984;35:695-701.
9. Plumb DC. Cyclosporine. In: Veterinary drug handbook. 3rd ed. Ames, Iowa: Iowa State University Press, 1999;156-159.
10. Barri YM, Ramos EL, Balagtas RS, et al. Cimetidine or ranitidine in renal transplant patients receiving CyA. Clin Transpl 1996; 10:34-38.
11. D'Souza MJ, Pollock SH, Solomon HM: CyA-cimetidine interaction. Drug Metab Dispos 1988;16:57-59.
12. 2-receptor antagonists (cimetidine, ranitidine, and famotidine) in Sprague-Dawley rats. Drugs Exp Clin Res 1989;15:159-164.
13. Henricsson S, Lindholm A, Aravoglou M. CyA metabolism in human liver microsomes and its inhibition by other drugs. Pharmacol Toxicol 1990;66:49-52.
14. Reichenspurner H, Meiser BM, Muschiol F, et al. The influence of gastrointestinal agents on resorption and metabolism of CyA after heart transplantation: experimental and clinical results. J Heart Lung Transplant 1993;12:987-992.
15. 2 receptor antagonists on the disposition of cyclosporin A in the in situ perfused rat liver model. Biopharm Drug Dispos 1995;16:719-733.
16. White JV, Ravis Wr, Nachreiner R, et al. CyA pharmacokinetics in normal and pancreatectomized dogs. Transplantation 1986;42:390-395.
17. Shaefer MS, Rossi SJ, McGuire TR, et al. Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and CyA in healthy men. Ann Pharmacother 1995;29:1088-1091.
18. Freeman D, Laupacis A, Keown P, et al. Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol. 1984;18:887-893.
19. Jarowenko M, Van Buren C, Kramer G, et al. Ranitidine, cimetidine, and the CyA-treated recipient. Transplantation 1986; 35:311-312.
20. Kronbach T, Fischer V, Meyer U. CyA metabolism in human liver: identification of a cytochrome P-450 III A gene family as the major CyA-metabolizing enzyme explains interactions of CyA with other drugs. Clin Pharmacol Ther 1988;43:630-635.
21. Chang T, Levine M, Bandieri S, et al. Selective inhibition of rat hepatic microsomal cytochrome P-450. II. Effect of the in vitro administration of cimetidine. J Pharmacol Exp Ther 1992;260: 1450-1455.
22. Chang T, Levine M, Bandieri S, et al. Selective inhibition of rat hepatic microsomal cytochrome P-450. I. Effect of the in vivo administration of cimetidine. J Pharmacol Exp Ther 1992;260: 1441-1449.
23. Watkins PB. The role of cytochromes P-450 in cyclosporine metabolism. J Am Acad Dermatol 1990;23:1301-1311.
24. Lown KS, Mayo R, Leichtman A, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of CyA. Clin Pharmacol Ther 1997;62:248-260.
25. Collett A, Higgs N, Sims E, et al. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in the rat intestine and the human colonie cell line Caco2. J Pharmacol Exp Ther 1999;288:171-178.
26. Vonderscher J, Meinzer A. Rationale for the development of Sandimmune Neoral. Transplant Proc 1994;26:2925-2927.
27. Gulliver WP, Murphy GF, Hannaford VA, et al. Increased bioavailability and improved efficacy, in severe psoriasis, of a new microemulsion formulation of cyclosporin. Br J Dermatol 1996; 135(suppl):35-39.
28. Chawla M, Ali M, Marks R. Comparison of the steady state pharmacokinetics of two formulations of cyclosporin in patients with atopic dermatitis. Br J Dermatol 1996;135(suppl):9-14.
29. Turgeon DK, Normolle DP, Leichtman AB, et al. Erythromycin breath test predicts oral clearance of CyA in kidney transplant recipients. Clin Pharmacol Ther 1992;52:471-478.
30. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994;22:947-955.
31. Thummel KE, Shen DD, Podoll TD, et al. Use of midazolam as a human cytochrome P450 3A probe. I: in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994; 271:549-56.
32. Gregory CR. Immunosuppressive agents. In: Kirk RW, Bonagura JD, eds. Current veterinary therapy XIII. Small animal practice. Philadelphia: WB Saunders Co, 2000;509-513.
33. Bennett WM, Norma DJ. Action and toxicity of CyA. Ann Rev Med 1986;37:215-224.